Immuron
ASX:IMCMelbourne, Australia· Est.
Australian biotech delivering oral polyclonal antibodies from bovine colostrum for GI disease prevention and treatment.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian biotech delivering oral polyclonal antibodies from bovine colostrum for GI disease prevention and treatment.
GastrointestinalInfectious Diseases
Technology Platform
Hyper‑immune bovine colostrum polyclonal IgG antibodies produced by immunising cows with pathogen‑specific vaccines and formulated for oral delivery to the GI tract.
Opportunities
Expansion of the oral polyclonal antibody platform into new GI infections and licensing to global partners could drive significant revenue growth.
Risk Factors
Regulatory hurdles for bovine‑derived therapeutics, supply‑chain BSE compliance, and competition from other hyperimmune colostrum products pose key risks.
Competitive Landscape
Few companies offer oral, pathogen‑specific polyclonal antibodies; Immuron’s patented platform and established commercial products provide a differentiated, low‑cost alternative to antibiotics.